Back to Browse Journals » International Journal of Nanomedicine » Volume 7
Preparation and evaluation of polymeric microparticulates for improving cellular uptake of gemcitabine
Authors Lim JH, You SK, Baek JS, Hwang CJ, Na YG, Shin SC, Cho CW
Received 1 February 2012
Accepted for publication 3 March 2012
Published 7 May 2012 Volume 2012:7 Pages 2307—2314
DOI https://doi.org/10.2147/IJN.S30465
Review by Single-blind
Peer reviewer comments 4
Ji-Ho Lim1,*, Sung-Kyun You1,*, Jong-Suep Baek1, Chan-Ju Hwang1, Young-Guk Na1, Sang-Chul Shin2, Cheong-Weon Cho1
1College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Gungdong, Yuseonggu, Daejeon, South Korea, 2College of Pharmacy, Chonnam National University, Buggu, Gwangju, South Korea
*These authors contributed equally to this work
Background: Gemcitabine must be administered at high doses to elicit the required therapeutic response because of its very short plasma half-life due to rapid metabolism. These high doses can have severe adverse effects.
Methods: In this study, polymeric microparticulate systems of gemcitabine were prepared using chitosan as a mucoadhesive polymer and Eudragit L100-55 as an enteric copolymer. The physicochemical and biopharmaceutical properties of the resulting systems were then evaluated.
Results: There was no endothermic peak for gemcitabine in any of the polymeric gemcitabine microparticulate systems, suggesting that gemcitabine was bound to chitosan and Eudragit L100-55 and its crystallinity was changed into an amorphous form. The polymeric gemcitabine microparticulate system showed more than 80% release of gemcitabine in 30 minutes in simulated intestinal fluid. When mucin particles were incubated with gemcitabine polymeric microparticulates, the zeta potential of the mucin particles was increased to 1.57 mV, indicating that the polymeric gemcitabine microparticulates were attached to the mucin particles. Furthermore, the F53 polymeric gemcitabine microparticulates having 150 mg of chitosan showed a 3.8-fold increased uptake of gemcitabine into Caco-2 cells over 72 hours compared with gemcitabine solution alone.
Conclusion: Overall, these results suggest that polymeric gemcitabine microparticulate systems could be used as carriers to help oral absorption of gemcitabine.
Keywords: gemcitabine, polymeric microparticulates, mucoadhesive, enteric coating, cellular uptake, oral absorption
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Other articles by this author:
Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection
Baek JS, Kim JH, Park JS, Cho CW
International Journal of Nanomedicine 2015, 10:5397-5405
Published Date: 26 August 2015
Practical preparation procedures for docetaxel-loaded nanoparticles using polylactic acid-co-glycolic acid
Keum CG, Noh YW, Baek JS, Lim JH, Hwang CJ, Na YG, Shin SC, Cho CW
International Journal of Nanomedicine 2011, 6:2225-2234
Published Date: 7 October 2011
Readers of this article also read:
Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitus
Jeong HR, An SSA
Clinical Interventions in Aging 2015, 10:1873-1879
Published Date: 19 November 2015
Hematuria following Botox treatment for upper limb spasticity: a case report
Lo TC, Yeung ST, Lee S, Chang EY
Journal of Pain Research 2015, 8:619-622
Published Date: 14 September 2015
Emerging and future therapies for hemophilia
Carr ME, Tortella BJ
Journal of Blood Medicine 2015, 6:245-255
Published Date: 3 September 2015
Mutations in presenilin 2 and its implications in Alzheimer’s disease and other dementia-associated disorders
Cai Y, An SSA, Kim SY
Clinical Interventions in Aging 2015, 10:1163-1172
Published Date: 14 July 2015
Acquired hemophilia A: emerging treatment options
Janbain M, Leissinger CA, Kruse-Jarres R
Journal of Blood Medicine 2015, 6:143-150
Published Date: 8 May 2015
A new recombinant factor VIII: from genetics to clinical use
Santagostino E
Drug Design, Development and Therapy 2014, 8:2507-2515
Published Date: 12 December 2014
Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries
Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M
Patient Preference and Adherence 2014, 8:1713-1720
Published Date: 12 December 2014
Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A
Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S
Neuropsychiatric Disease and Treatment 2014, 10:865-867
Published Date: 16 May 2014
A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project
Lentz SR, Tandra A, Gut RZ, Cooper DL
Journal of Blood Medicine 2014, 5:1-3
Published Date: 13 January 2014
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al
International Journal of Nanomedicine 2010, 5:581-591
Published Date: 6 August 2010
